Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in Connecticut?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes. A Connecticut resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Connecticut-licensed provider, including by telehealth under Connecticut General Statutes section 19a-906, which covers synchronous, asynchronous store-and-forward, and remote monitoring care. Compounded peptides are available when eligible under federal 503A rules and dispensed by a Connecticut pharmacy or a registered nonresident pharmacy; a nonresident pharmacy that compounds sterile products such as injectable peptides for Connecticut patients must file a sterile compounding addendum and receive written approval from the Department of Consumer Protection and the Commission of Pharmacy first (section 20-633b).

Regulatory: Telehealth allowedRegulatory: Async allowedRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 28, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous allowed
Compounded GLP-1
Limited

Can a Connecticut resident get peptides by telehealth?

Section 19a-906 defines telehealth to include synchronous interactions, asynchronous store and forward transfers, and remote patient monitoring, and excludes fax, texting, and email. A telehealth provider may provide telehealth services only when communicating through real-time, interactive, two-way communication technology or store and forward technologies, with access to or knowledge of the patient's medical history and health record, while meeting the standard of care expected for in-person care and obtaining consent at the first telehealth interaction. The statute bars telehealth prescribing of schedule I, II, and III controlled substances except schedule II or III drugs used as part of medication-assisted treatment or to treat psychiatric disabilities or substance use disorders (as amended by Public Act 25-168, effective June 30, 2025); peptides in this database are not controlled, so that limit does not affect GLP-1 or compounded peptide prescriptions. The temporary authorization that let registered out-of-state mental and behavioral health providers treat Connecticut patients ran through June 30, 2025, so a prescriber needs a Connecticut license. The statute does not mention online questionnaires. This record classifies asynchronous prescribing as allowed because section 19a-906(b)(1) names store and forward technologies alongside real-time communication as a permitted way to provide telehealth services, subject to the same standard of care as in-person care. [4]

How does the Connecticut pharmacy board treat compounding?

Compounding regulator for Connecticut
BoardConnecticut Commission of Pharmacy (Department of Consumer Protection, Drug Control Division)
Eligible substancesFollows the federal 503A framework

Connecticut regulates pharmacies through the Department of Consumer Protection and the Commission of Pharmacy under chapter 400j of the General Statutes. Connecticut has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Two Connecticut rules matter for injectable peptides. First, a pharmacy outside Connecticut must hold a nonresident pharmacy registration under section 20-627 and disclose whether it dispenses sterile pharmaceuticals into the state. Second, section 20-633b defines a sterile compounding pharmacy to include registered nonresident pharmacies and requires a nonresident applicant that intends to compound sterile products for Connecticut patients to file an addendum, provide proof of a passed home-state inspection, and wait for written approval from the Department and the Commission before shipping. Connecticut's sterile compounding regulations (Regulations of Connecticut State Agencies sections 20-576-64 to 20-576-68, adopted 2011) apply to pharmacies licensed under section 20-594 and require compliance with the current USP chapter 797, a policy and procedure manual that complies with chapter 797, a two-week limit on compounded products supplied to practitioners for office use, and at least 35 open hours a week unless waived. Those regulations do not set separate compounding standards for nonresident pharmacies; a nonresident sterile compounder is governed by the section 20-633b addendum, inspection, and approval process described above. [1] [5] [6] [7] [8] [10]

Can you get compounded GLP-1s in Connecticut?

Regulatory: Compounded GLP-1 limited

Because compounded GLP-1 injections are sterile preparations, an out-of-state pharmacy shipping them to Connecticut must have an approved sterile compounding addendum under section 20-633b in addition to its nonresident registration. [6] [7] [13]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Connecticut?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in Connecticut

What you'll actually find in Connecticut, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [18] [19] [20]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [21]

What Connecticut has done

PeptideAgent has not found a board or legislative action on peptides in Connecticut.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [23] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [24] [25] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in Connecticut. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. [4] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the Connecticut Commission of Pharmacy (Department of Consumer Protection, Drug Control Division); its license search: FDA BeSafeRx: state board of pharmacy license lookups. [22]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [21]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [11] [26] [27]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [22] [28] [29]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [20] [29] [30]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [21] [31] [32] [33] [34] [35]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [21]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [22]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [20]
  • Pharmacy: Is this made for me on a prescription written in my name? [30]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [20] [29]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [20]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in Connecticut?

Only Connecticut-licensed pharmacies and registered nonresident pharmacies may dispense prescription drugs to Connecticut patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and fall outside Connecticut's sterile compounding approval system. Connecticut law also bars the sale directly: under the Connecticut Food, Drug and Cosmetic Act, section 21a-110 provides that no person shall sell, deliver, offer for sale, hold for sale, or give away any new drug unless an application for it has been approved under section 355 of the federal act or, for a drug not subject to the federal act, a state application has been filed with the Commissioner of Consumer Protection. The Connecticut Attorney General has used the Connecticut Unfair Trade Practices Act (Conn. Gen. Stat. 42-110a and following) against sellers of research-grade GLP-1s, including a 2025 settlement with an online distributor and a May 2026 settlement under which an international online trade platform agreed to stop GLP-1 sales to US consumers and remove such listings. The same May 2026 announcement included a settlement with a medical spa that stopped advertising and prescribing compounded semaglutide and tirzepatide. [6] [9] [14] [15]

Peptide-specific notes for Connecticut

Peptide-specific notes for Connecticut
PeptideNote
SemaglutideAvailable branded by prescription from a Connecticut-licensed provider, including after an asynchronous store and forward evaluation under section 19a-906 that meets the in-person standard of care, with access to or knowledge of the patient's medical history and health record. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025, and out-of-state compounded vials require an approved sterile compounding addendum. [4] [7] [13]

Frequently asked questions

Does Connecticut allow asynchronous telehealth prescribing for GLP-1 drugs?

Yes. Section 19a-906 defines telehealth to include asynchronous store and forward transfers and lets a telehealth provider communicate through store and forward technologies. Semaglutide and tirzepatide are not controlled substances, so a Connecticut-licensed provider may prescribe them after an evaluation that meets the in-person standard of care and includes access to or knowledge of your medical history and health record. The statute does not mention online questionnaires. [4]

Can an out-of-state telehealth doctor still treat me in Connecticut?

Only with a Connecticut license. The temporary authorization in section 19a-906 for registered out-of-state mental and behavioral health providers ran through June 30, 2025. Check the provider on the Department of Public Health license lookup before paying. [4]

What does an out-of-state pharmacy need to send me injectable compounded peptides in Connecticut?

A nonresident pharmacy registration under section 20-627 plus an approved sterile compounding addendum under section 20-633b, which requires proof of a passed home-state inspection and written approval from the Department of Consumer Protection and the Commission of Pharmacy before any sterile product is shipped. [6] [7]

Can a Connecticut pharmacy compound BPC-157?

Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Connecticut has no separate state bulks list, so peptide eligibility follows the federal 503A framework. [11] [12] [16] [17]

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]Connecticut Commission of Pharmacy, Department of Consumer Protection
  2. [2]Connecticut General Statutes section 19a-906, Telehealth services
  3. [3]Connecticut General Statutes chapter 368ll, revision to January 1, 2025 (section 19a-906 before the 2025 amendments)
  4. [4]Connecticut General Statutes, 2026 Supplement, chapter 368ll, section 19a-906, Telehealth services (as amended by P.A. 25-97 and P.A. 25-168), accessed 2026-09-30
  5. [5]Connecticut General Statutes chapter 400j, Pharmacy
  6. [6]Connecticut General Statutes section 20-627, Nonresident pharmacy registration
  7. [7]Connecticut General Statutes section 20-633b, Sterile compounding pharmacies
  8. [8]Regulations of Connecticut State Agencies sections 20-576-64 to 20-576-68, Sterile compounding pharmacies (standards in section 20-576-66, adopted effective July 12, 2011), accessed 2026-09-22
  9. [9]Connecticut General Statutes chapter 418 (Connecticut Food, Drug and Cosmetic Act), section 21a-110, New drugs, accessed 2026-09-22
  10. [10]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Are peptides legal in Connecticut?. https://peptideagent.ai/legal/connecticut
HTML link
<a href="https://peptideagent.ai/legal/connecticut">Are peptides legal in Connecticut?</a>, PeptideAgent, updated October 28, 2026.